MedTrace Logo

Affect of Duavive on Mood & Anxiety Symptoms

NCT04478305 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2024-12-03

No results posted yet for this study

Summary

This study evaluates the impact of conjugated estrogens/ bazedoxifene (CE/ BZA) on the mood (depression and anxiety) in peri- and early menopausal women.

Conditions

  • Menopause
  • Depression, Anxiety
  • Sleep
  • Menopause Related Conditions

Interventions

DRUG

Duavive 0.45Mg-20Mg Tablet

Duavee, marketed as Duavive in Canada.

Sponsors & Collaborators

Principal Investigators

  • Alison Shea, MD · St. Joseph's Healthcare, McMaster University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
45 Years
Max Age
60 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-03
Primary Completion
2025-12-31
Completion
2025-12-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04478305 on ClinicalTrials.gov